Long-Term Outcomes of Lenalidomide-Dexamethasone in Combination With Radiotherapy in Solitary Plasmacytoma
International Journal of Radiation Oncology*Biology*Physics · 2026-10
DOI: 10.1016/j.ijrobp.2026.10.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-10. Verfasst von Pierre Loap und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Institut Curie, Paris, France; Imaging, Innovative Radiotherapy and System Medicine, UMR9029 CNRS, U1353 Inserm, Ve…. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Radiotherapy achieves excellent local control in solitary plasmacytoma, but systemic progression remains a major limitation. We evaluated the long-term association between lenalidomide-dexamethasone combined with radiotherapy and disease outcomes. MATERIALS AND METHODS: This retrospective analysis of a prospectively maintained database included 75 consecutive patients with solitary plasmacytoma treated between 2004 and 2025. All patients underwent bone marrow assessment, serum free light-chain testing, and magnetic resonance imaging, with PET/CT routinely incorporated into staging from late 2008 onward. Patients received radiotherapy alone (n=42) or radiotherapy combined with lenalidomide-dexamethasone (n=33). Primary endpoints were progression-free survival and multiple myeloma-free survival. Systemic progression-free survival, defined by progression to multiple myeloma, multiple plasmacytomas, or distant solitary plasmacytoma, was additionally evaluated. RESULTS: Median follow-up was 6.31 years. Only three local recurrences occurred. Lenalidomide-dexamethasone was associated with longer progression-free survival (HR, 0.315; 95% CI, 0.128-0.775; p=0.012), with 10-year rates of 71.8% versus 26.7% after radiotherapy alone. Among the six patients progressing after combined treatment, three (50.0%) developed multiple myeloma and three (50.0%) developed multiple plasmacytomas. Multiple myeloma-free survival did not differ significantly between groups (10-year rates, 86.6% vs 65.9%; p=0.19). CONCLUSION: Lenalidomide-dexamethasone combined with radiotherapy was associated with sustained improvement in progression-free survival in solitary plasmacytoma. These long-term findings support prospective evaluation of upfront lenalidomide-dexamethasone in combination with radiotherapy for solitary plasmacytoma.
Autor:innen und Institutionen
- Department of Radiation Oncology, Institut Curie, Paris, France; Imaging, Innovative Radiotherapy and System Medicine, UMR9029 CNRS, U1353 Inserm, Versailles Saint-Quentin University, PSL Research University, Institut C…
- Department of Radiation Oncology, Institut Curie, Paris, France.
- Hematology Department, Hospital Cochin, Paris, France.
Zitieren
APA
Loap, P., Laroze, S., Bouscary, D., Vignon, M., & Kirova, Y. (2026). Long-Term Outcomes of Lenalidomide-Dexamethasone in Combination With Radiotherapy in Solitary Plasmacytoma. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.10.030
Vancouver
Loap P, Laroze S, Bouscary D, Vignon M, Kirova Y. Long-Term Outcomes of Lenalidomide-Dexamethasone in Combination With Radiotherapy in Solitary Plasmacytoma. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.10.030
BibTeX
@article{Loap2026,
author = {Loap, Pierre and Laroze, Sebastien and Bouscary, Didier and Vignon, Marguerite and Kirova, Youlia},
title = {Long-Term Outcomes of Lenalidomide-Dexamethasone in Combination With Radiotherapy in Solitary Plasmacytoma},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
doi = {10.1016/j.ijrobp.2026.10.030}
}
EUVIMED